Clinical trials: Resistant Hypertension
Pulmonary Hypertension
Evaluate Effect of Optison on Pulmonary Artery Systolic Pressure (PASP) and Pulmonary Vascular Resistance (PVR).
The design of this study is to conduct a comprehensive safety evaluation of the pulmonary hemodynamic effects of Optison. The study is being conducted in subjects referred for cardiac catheterization for clinical reasons.
- Trial name
- NCT00878878
- Testing
- Optison (Perflutren Protein-Type A Microspheres Injectable Suspension), Dextrose
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- GE Healthcare
Hypertension, Pulmonary
Insulin Resistance in Pulmonary Arterial Hypertension
The purpose of this study is to evaluate 1) the incidence of insulin resistance (a pre-diabetic state) in patients with pulmonary hypertension, and 2) test the utility of a validated PH therapy (Tracleer) versus Pioglitazone in…
- Trial name
- NCT00825266
- Testing
- bosentan, Pioglitazone
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Stanford University
Hypertension, Metabolic Syndrome X
Clinical EvaluatioN of TElmisartan-based Antihypertensive Regimen
To determine the efficacy and safety of telmisartan-based treatment among patients with metabolic syndrome in actual setting in Philippines.
- Trial name
- NCT00613314
- Where
- 122 sites in Philippines
- Volunteers
- 15,268 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Hypertension
Investigation of H01 in Adults With Pulmonary Hypertension Including Interstitial Lung Disease (The SATURN Study).
This study is a prospective, randomized, double-blind, study of H01 (Hymecromone) in adults with pulmonary hypertension (PH). The primary objective of this study is to evaluate the safety and tolerability of oral H01 and the…
- Trial name
- SATURN (NCT05128929)
- Testing
- Hymecromone (H01)
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Stanford University
Obesity, Metabolic Syndrome X
Drug Therapy Induced Weight Loss to Improve Blood Vessel Function in Subjects With Obesity
Obesity is common (>30% of US adults), contributes to substantial morbidity and mortality, but is difficult to treat. Partly this is due to the transient, arduous and modest nature of lifestyle interventions.
- Trial name
- REVIVE (NCT01351753)
- Testing
- Metformin, Orlistat, Topiramate
- Where
- United States
- Volunteers
- 128 people
- Sponsor
- University of Iowa
Obstructive Sleep Apnea, Resistant Hypertension
Etiology of Sleep Apnea-related Hyperaldosteronism - BP Treatment
Hypertension affects an estimated 60-70 million Americans, predisposing them to potentially life threatening cardiovascular complications.
- Conditions
- Obstructive Sleep Apnea, Resistant Hypertension, Hyperaldosteronism
- Trial name
- NCT01897727
- Testing
- Spironolactone, BP medication uptitration
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- University of Alabama at Birmingham
Resistant Hypertension
A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its Safety
The goal of this clinical trial is to show the blood pressure lowering effect of aprocitentan, a new drug, when added to other anti-hypertensive drugs of patients with difficult to control (resistant) high blood pressure…
- Trial name
- PRECISION (NCT03541174)
- Testing
- Aprocitentan 12.5 mg, Aprocitentan 25 mg
- Where
- 159 sites in United States, Australia and 18 more
- Volunteers
- 730 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Hypertension
Treatment of Resistant Hypertension Using a Radiofrequency Percutaneous Transluminal Angioplasty Catheter
The Study objective is to assess the performance of the Vessix V2 Renal Denervation System for the treatment of uncontrolled hypertension using an innovative percutaneous Radio Frequency (RF) balloon catheter renal denervation…
- Trial name
- REDUCE-HTN (NCT01541865)
- Testing
- Renal Denervation
- Where
- 26 sites in Australia, Austria and 6 more
- Volunteers
- 146 people
- Sponsor
- Boston Scientific Corporation
Morbid Obesity, Metabolic Syndrome X
Randomized Comparison of Laparoscopic Sleeve Gastrectomy and Gastric Bypass for Morbid Obesity
Bariatric surgery is the most effective treatment for morbid obesity. Roux-en-Y gastric bypass (RYGB) is a bariatric procedure with known safety and effectiveness.
- Conditions
- Morbid Obesity, Metabolic Syndrome X, Diabetes Mellitus, Dyslipidemia
- Trial name
- NCT01806506
- Testing
- Laparoscopic sleeve gastrectomy, Roux-en-Y Gastric Bypass
- Where
- Poland
- Volunteers
- 72 people
- Sponsor
- Medical University of Warsaw
Systemic Arterial Hypertension, Hypertension Resistant to Conventional Therapy
Renin-angiotensin-aldosterone System Polymorphisms in Resistant Hypertension and Adverse Cardiovascular Events
Renin-angiotensin-aldosterone system (RAAS) polymorphisms influence 24h arterial pressure fluctuation. Resistant systemic arterial hypertension (RSAH) has an increased risk of end organ damage and unfavourable prognosis, whereas…
- Conditions
- Systemic Arterial Hypertension, Hypertension Resistant to Conventional Therapy, Myocardial Infarction, Stroke
- Trial name
- GENHART (NCT01173029)
- Testing
- Anti-hypertensive drug treatment
- Where
- Brazil
- Volunteers
- 92 people
- Sponsor
- Universidade Gama Filho
Diabetes Mellitus, Hypertension
Impact of INsulin Sensitivity on Cardiovascular Risk Markers During 10-20 Years of FOllow up
The purpose of this study is to identify risk factors for insulin resistance and to investigate the influence of insulin sensitivity on development of cardiovascular risk markers like blood pressure, heart rate, body build…
- Conditions
- Diabetes Mellitus, Hypertension, Ischemic Heart Disease, Stroke
- Trial name
- INFO (NCT01412554)
- Where
- Norway
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Oslo University Hospital
Metabolic Syndrome
Evaluation of 3-V Bioscience-2640 to Reduce de Novo Lipogenesis in Subjects With Characteristics of Metabolic Syndrome
Metabolic syndrome increases the risk for development of heart disease. Another condition associated with metabolic syndrome is fatty liver disease which is also referred to as nonalcoholic fatty liver disease (NAFLD).
- Trial name
- NCT02948569
- Testing
- 3-V Bioscience-2640
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Missouri-Columbia
Pulmonary Arterial Hypertension
Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Participants
The purpose of this study was to investigate the effects of QTI571 (imatinib) on pharmacokinetics of bosentan and sildenafil at steady state when co-administered to participants with pulmonary arterial hypertension.
- Trial name
- NCT01392469
- Testing
- Imatinib, Sildenafil, Bosentan
- Where
- 11 sites in United States, Australia and 5 more
- Volunteers
- 21 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
Efficacy and Safety of Radiofrequency Renal Denervation in Drug Resistant Hypertension
Single-center, single group study of the efficacy and safety of transcatheter renal denervation for treatment of patients with essential hypertension uncontrolled despite combined pharmacotherapy including 3 or more hypotensive…
- Trial name
- NCT01499810
- Testing
- Bilateral radiofrequency sympathetic renal denervation
- Where
- Russia
- Volunteers
- 53 people
- Sponsor
- Tomsk National Research Medical Center of the Russian Academy of Sciences
Hypertension
Renal Denervation for Management of Drug-Resistant Hypertension
INSPiRED is a multicenter parallel-group trial comparing usual medical treatment (control group) or usual medical treatment plus renal denervation (intervention).
- Trial name
- INSPiRED (NCT01505010)
- Testing
- Renal denervation
- Where
- 2 sites in Belgium
- Volunteers
- 17 people
- Sponsor
- KU Leuven
Pulmonary Hypertension (World Health Organization Group 2), Heart Failure
A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2
This study is intended to assess the ability of AZD3427 to reduce pulmonary vascular resistance (PVR) after 24 weeks of treatment in participants with heart failure (HF) and pulmonary hypertension (PH) Group 2
- Trial name
- Re-PHIRE (NCT05737940)
- Testing
- AZD3427
- Where
- 60 sites in United States, Austria and 12 more
- Volunteers
- 260 people
- Sponsor
- AstraZeneca
Chronic Thromboembolic Pulmonary Hypertension, CTEPH
Riociguat in Patients With Operable CTEPH Prior to Pulmonary Endarterectomy (PEA Bridging Study)
This is a randomised, double-blind, placebo-controlled, multicentre, multinational, prospective study in patients with operable chronic thromboembolic pulmonary hypertension (CTEPH) prior to pulmonary endarterectomy (PEA) with…
- Trial name
- NCT03273257
- Testing
- Riociguat, Pulmonary endarterectomy
- Where
- 4 sites in United States, France and 2 more
- Volunteers
- 14 people
- Sponsor
- International CTEPH Association
Metabolic Syndrome X, Overweight
Atheroma Reduction With Chloroquine in Patients With the Metabolic Syndrome (ARCH-MS)
Metabolic syndrome consists of a group of co-occuring conditions that increase an individual's risk of developing heart disease, stroke, and diabetes.
- Conditions
- Metabolic Syndrome X, Overweight, Hypertension, Dyslipidemias
- Trial name
- ARCH-MS (NCT00455403)
- Testing
- Chloroquine
- Where
- United States
- Volunteers
- 357 people
- Sponsor
- Washington University School of Medicine
Resistant Hypertension
A Study Of Different Doses Of TBC3711 In Patients With Uncontrolled High Blood Pressure Already Taking Medications For High Blood Pressure.
The study was to determine the safe and effective dose of TBC3711 in patients with uncontrolled high blood pressure while already taking blood pressure medications.
- Trial name
- NCT00272961
- Testing
- TBC3711
- Where
- 12 sites in United States
- Volunteers
- 60 people
- Sponsor
- Pfizer
Metabolic Syndrome, Dyslipidemia
Impact of Consumption of Beta-glucans on the Intestinal Microbiota and Glucose and Lipid Metabolism
The purpose of this study is to investigate if daily consumption of barley beta-glucans effect lipid and glucose metabolism and alter intestinal microbiota composition in participants with metabolic syndrome or with high risk for…
- Conditions
- Metabolic Syndrome, Dyslipidemia, Obesity, Abdominal, Hyperglycemia
- Trial name
- NCT02041104
- Testing
- Bread with added beta-glucans
- Where
- 3 sites in Slovenia
- Volunteers
- 51 people
- Sponsor
- Mlinotest Zivilska Industrija d.d.